

References

- 1- Aime-Sempe C, Folliguet T, Rucker-Martin C et al. (1999):** Myocardial cell death in fibrillating and dilated human right atria. *J Am Coll Cardiol*; 34:1577–1586.
- 2- Al-Khatib SM, Pieper KS, Lee KL et al. (2001):** Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: Results from the PURSUIT trial. *Am J Cardiol*; 88: 76–79.
- 3- Allessie M, Ausma J and Schotten U (2002):** Electrical, contractile and structural remodeling during atrial fibrillation. *Cardiovasc Res*; 54:230–246.
- 4- Alpert JS, Thygesen K and Antman E (2000):** Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *J Am Coll Cardiol*; 36: 959–969.
- 5- Anne W, Willems R, Van der MN, et al. (2004):** Atrial fibrillation after radio-frequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics. *Heart*; 90:1025–1030.
- 6- Antman EM, Anbe DT, Armstrong PW et al. (2004):** ACC/AHA Guidelines for the management of patients with ST-elevation myocardial infarction. Executive summary: a report of the American College of Cardiology /American Heart Association Task Force on practice guidelines. *Circulation*; 10:588–636.
- 7- Antman EM and Braunwald E. (2005):** ST-elevation myocardial infarction: pathology, patho-physiology, and clinical features; arrhythmias. Braunwald's heart disease: a textbook of cardiovascular medicine. 7th ed. Philadelphia: WB Saunders; 1207–1218.
- 8- Antonielli E, Pizzuti A, Bassignana A et al. (1999):** Trans-esophageal echocardiographic evidence of more pronounced left atrial stunning after chemical (propafenone) rather than electrical attempts at cardioversion from atrial fibrillation. *Am J Cardiol*; 84:1092–1010.

- 9- Arnsdorf MF and Ganz LI. (2006):** Approach to narrow QRS complex tachycardias. Up to date. 14.2 ed.
- 10- Asanin M, Perunicic J, Mrdovic I et al. (2005):** Prognostic significance of new atrial fibrillation and its relation to heart failure following acute myocardial infarction. *The European Journal of Heart Failure*; 7: 671–676.
- 11- Bellet S (1971):** Clinical Disorders of the Heart Beat. 3rd ed. Philadelphia: Lea & Febiger.
- 12- Blomström-Lundqvist, Scheinman MM and Aliot EM (2003):** ACC/AHA/ESC guidelines for the management of patients with supra-ventricular arrhythmias. *J Am Coll Cardiol*; 42: 1493–1531.
- 13- Boersma E, Harrington RA, Moliterno DJ et al. (2002):** Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomized clinical trials. *Lancet*; 359:189-198.
- 14- Braunwald E, Antman E, Beasley J et al. (2000):** ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. *J Am Coll Cardiol*; 36:970-1062.
- 15- Braunwald E, Antman EM, Beasley JW et al. (2002):** ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction—summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients with Unstable Angina). *J Am Coll Cardiol*; 40:1366–1374.
- 16- Brazdzionyte J and Baksyte G (2004):** Risk assessment in acute myocardial infarction. *Medicina (Kaunas)*; 40:121–126.
- 17- Brookes CI, White PA, Staples M et al. (1998):** Myocardial contractility is not constant during spontaneous atrial fibrillation in patients. *Circulation*; 98:1762–1768.

- 18- Budaj A, Flasinka K, Gore JM et al. (2005):** for the GRACE Investigators Magnitude of and risk factors for in hospital and post-discharge stroke in patients with acute coronary syndromes. Findings from a Global Registry of Acute Coronary Events. *Circulation*; 111:3242–3247.
- 19- Cappato R (2009):** Atrial fibrillation complicating acute myocardial infarction: How should it be interpreted and how should it be treated and prevented? *Eur Heart J*, 30: 1035–1037.
- 20- Celik S, Erdol C, Baykan M et al. (2001):** Relation between paroxysmal atrial fibrillation and left ventricular diastolic function in patients with acute myocardial infarction. *Am J Cardiol*; 88:160–162.
- 21- Chase M, Zogby K, Shofer FS et al. (2006):** Prospective validation of the TIMI risk score in the emergency department chest pain population. *Ann Emerg Med*; 48:252- 259.
- 22- Cheitlin MD, Armstrong WF, Aurigemma GP et al. (2003):** ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography).
- 23- Chen YJ, Chen SA, Chen YC et al. (2001):** Effects of rapid atrial pacing on the arrhythmogenic activity of single cardiomyocytes from pulmonary veins: implication in initiation of atrial fibrillation. *Circulation*; 104:2849–2854.
- 24- Chilton R and O'Rourke RA (2001):** The expanding role of HMG-CoA reductase inhibitors (statins) in the prevention and treatment of ischemic heart disease. *Curr Probl Cardiol*; 26:729-764.
- 25- Collins LJ, Silverman DI, Douglas PS et al. (1995):** Cardioversion of non-rheumatic atrial fibrillation. Reduced thrombo-embolic complications with 4 weeks of pre-cardioversion anticoagulation are related to atrial thrombus resolution. *Circulation*; 92:160–163.

- 26- Compell M and Machin L (1993):** Medical statistics: A common approach. Second edition John Wiley and Sons Chichester, New York, Brisbane, Toranta and Singapora.
- 27- Cox JL, Canavan TE, Schuessler RB et al. (1991):** The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiology mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. *J Thorac Cardiovasc Surg*; 101:406-426.
- 28- Crenshaw BS, Ward SR, Granger CB et al. (1997):** Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. *J Am Coll Cardiol*; 30:406–413.
- 29- Crijns HJ, Tjeerdsma G, De Kam PJ et al. (2000):** Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. *Eur Heart J*; 21:1238–1245.
- 30- Dell'Italia LJ, Rocic P and Lucchesi PA (2002):** Use of angiotensin-converting enzyme inhibitors in patients with diabetes and coronary artery disease. *Curr Probl Cardiol*; 27:1-36.
- 31- Dernellis J and Panaretou M (2001):** C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. *Acta Cardiol*; 56:375–380.
- 32- Dittrich HC, Pearce LA, Asinger RW et al. (1999):** Left atrial diameter in non-valvular atrial fibrillation: an echocardiographic study. Stroke Prevention in Atrial Fibrillation Investigators. *Am Heart J*; 137: 494–499.
- 33- Dunn MI and Marcum JL (2002):** Atrial mechanical performance following internal and external cardioversion of atrial fibrillation: its relationship to peripheral embolization and acute cerebrovascular accident. *Chest*; 121:1–3.
- 34- Dziewierz A, Siudak Z, Rakowski T et al. (2010):** Atrial fibrillation and mortality in ACS. *Cardiol J*; 17:57–64

- 35- Fang MC, Singer DE, Chang Y et al. (2005):** Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the Anti-coagulation and Risk factors In Atrial fibrillation (ATRIA) study. *Circulation*; 112:1687–1691.
- 36- Feigenbaum H (1994).** Echocardiography. 5th ed. Philadelphia, Pa: Lea & Febiger.
- 37- Fiore LD, Ezekowitz MD, Brophy MT et al. (2002):** Department of Veterans Affairs Cooperative Studies Program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: Primary results of the CHAMP Study. *Circulation*; 105:557-563.
- 38- Fogoros R. (2006):** Abnormal heart rhythms. In: Forgoros R, ed. Electrophysiologic testing. *Massachusetts: Blackwell*; 12–21.
- 39- Freidman MJ, Roeske WR, Sahn DJ, et al. (1982):** Accuracy of M-mode echocardiographic measurements of the left ventricle. *Am J Cardiol*; 49:416-423.
- 40- Friberg J, Buch P, Scharling H et al. (2003):** Rising rates of hospital admissions for atrial fibrillation. *Epidemiology*; 14:666–672.
- 41- Friberg J, Scharling H, Gadsboll N et al. (2003):** Sex-specific increase in the prevalence of atrial fibrillation (The Copenhagen City Heart Study). *Am J Cardiol*; 92:1419 –1423.
- 42- Furberg CD, Psaty BM, Manolio TA et al. (1994):** Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). *Am J Cardiol*; 74:236–241.
- 43- Fuster V, Rydén LE, Cannom DS et al. (2006):** ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). *Eur Heart J*; 27:1979–2030.

- 44- Gallagher MM, Hennessy BJ, Edvardsson N et al. (2002):** Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. *J Am Coll Cardiol*; 40:926–933.
- 45- Gami AS, Pressman G, Caples SM et al. (2004):** Association of atrial fibrillation and obstructive sleep apnea. *Circulation*; 110:364–367.
- 46- Go AS, Hylek EM, Phillips KA et al. (2001):** Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA*; 285: 2370 –2375.
- 47- Goldberg RJ, Yarzebski J, Lessard D et al. (2002):** Recent trends in the incidence rates of and death rates from atrial fibrillation complicating initial acute myocardial infarction: a community-wide perspective. *Am Heart J*; 143: 519 –527.
- 48- Goldman ME, Pearce LA, Hartz RG et al. (2000):** Trans-esophageal echocardiographic correlates of clinical risk of thrombo-embolism in non-valvular atrial fibrillation: Reduced flow velocity in the left atrial appendage. *Am Soc Echocardiogr*; 12:1080–1087.
- 49- Goto S, Tamura N, Eto K et al. (2002):** Functional significance of adenosine 5'-diphosphate receptor (P2Y₁₂) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ib alpha induced by conditions of high shear rate. *Circulation*; 105:2531-2536.
- 50- Grogan M, Smith HC, Gersh BJ et al. (1992):** Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. *Am J Cardiol*; 69:1570–1573.
- 51- Grundy SM, Cleeman JI, Merz CNB et al. (2004):** Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. *Circulation*; 110:227-239.
- 52- Gum PA, Kottke-Marchant K, Poggio ED et al. (2001):** Profile and prevalence of aspirin resistance in patients with cardiovascular disease. *Am J Cardiol*; 88:230-235.

- 53- Hart RG, Pearce LA, Miller VT et al. (2000):** Cardioembolic vs. non-cardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. *Cerebrovasc Dis*; 10:39–43.
- 54- Healey JS, Baranchuk A, Crystal E et al. (2005):** Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. *J Am Coll Cardiol*; 45:1832–1839.
- 55- Hioki M, Ikeshita M, Iedokoro Y et al. (1993):** Successful combined operation for mitral stenosis and atrial fibrillation. *Ann Thorac Surg*; 55:776-778.
- 56- Hirsh J, Warkentin TE, Shaughnessy SG et al. (2001):** Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. *Chest*; 119:64-94.
- 57- Hsu LF, Jais P, Keane D et al. (2004):** Atrial fibrillation originating from persistent left superior vena cava. *Circulation*; 109:828–832.
- 58- Hulten E, Jackson JL, Douglas K et al. (2006):** The effect of early, intensive statin therapy on acute coronary syndrome: A meta-analysis of randomized controlled trials. *Arch Intern Med*; 166:1814-1821.
- 59- Hunt D, Sloman G and Penington C (1978):** Effects of atrial fibrillation on prognosis of acute myocardial infarction. *Br Heart J*; 40: 303–7.
- 60- Jais P, Haissaguerre M, Shah DC et al. (1997):** A focal source of atrial fibrillation treated by discrete radiofrequency ablation. *Circulation*; 95: 572–576.
- 61- Jais P, Hocini M, Macle L et al. (2002):** Distinctive electrophysiological properties of pulmonary veins in patients with atrial fibrillation. *Circulation*; 106:2479–2485.
- 62- Kamkin A, Kiseleva I, Wagner KD et al. (2003):** Mechanically induced potentials in atrial fibroblasts from rat hearts are sensitive to hypoxia/ re-oxygenation. *Pflugers Arch*; 446:169–174.

- 63- Khan IA (2003):** Atrial stunning: determinants and cellular mechanisms. *Am Heart J*; 145:787–794.
- 64- Killip T and Kimball JT (1967):** Treatment of myocardial infarction in a coronary care unit. A two-year experience with 250 patients. *Am J Cardiol*; 20:457–464.
- 65- Kinjo K, Sato H, Ohnishi Y et al. (2003):** Prognostic significance of atrial fibrillation/atrial flutter in patients with acute myocardial infarction treated with percutaneous coronary intervention. *Am J Cardiol*; 92:1150 – 1154.
- 66- Kleiman NS and White HD (2005):** The declining prevalence of ST elevation myocardial infarction in patients presenting with acute coronary syndromes. *Heart*; 91:1121-1123.
- 67- Klein EA (2000):** Assessment of Cardioversion Using Trans-esophageal Echocardiography (TEE) multicenter study (ACUTE I): clinical outcomes at eight weeks. *J Am Coll Cardiol*; 36:324.
- 68- Klein GJ, Bashore TM, Seller TD et al. (1979):** Ventricular fibrillation in the Wolff-Parkinson-White syndrome. *N Engl J Med*; 301:1080–1085.
- 69- Kobayashi Y, Katoh T, Takano T et al. (1992):** Paroxysmal atrial fibrillation and flutter associated with acute myocardial infarction: hemodynamic evaluation in relation to the development of arrhythmias and prognosis. *Jpn Circ J*; 56:1–11.
- 70- Kochiadakis GE, Skolidis EI, Kalebubas MD et al. (2002):** Effect of acute atrial fibrillation on phasic coronary blood flow pattern and flow reserve in humans. *Eur Heart J*; 23:734–741.
- 71- Konings KT, Kirchhof CJ, Smeets JR et al. (1994):** High-density mapping of electrically induced atrial fibrillation in humans. *Circulation*; 89: 1665-1680.
- 72- Konomi S, Hiroaki K, Kiyotake I et al. (1997):** Clinical and prognostic significance of atrial fibrillation in acute myocardial infarction. *Am J Cardiol*; 80:1522–1527.

- 73- Kugelmass AD, Sadanandan S, Cannon CP et al. (2001):** Early invasive strategy improves outcomes in acute coronary syndrome patients with prior CABG: Results from TACTICS-TIMI 18. *Circulation*; 104:538-548.
- 74- Kumagai K, Nakashima H and Saku K (2004):** The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. *Cardiovasc Res*; 62:105–111.
- 75- Kyriakidis M, Barbetseas J, Antonopoulos A et al. (1992):** Early atrial arrhythmias in acute myocardial infarction. Role of the sinus node artery. *Chest*; 101:944–947.
- 76- Lang RM, Bierig M, Devereux RB, et al. (2005):** Recommendations for Chamber Quantification: a Report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. *J Am Soc Echocardiogr*; 18:1440-1463.
- 77- Lau DH, Huynh LT, Chew DP et al. (2009):** Prognostic Impact of Types of Atrial Fibrillation in Acute Coronary Syndromes. *Am J Cardiol*; 104:1317–1323.
- 78- Laurent G, Zeller M, Dentan G et al. (2005):** Prognostic impact of new onset atrial fibrillation in acute non-ST elevation myocardial infarction data from the RICO survey. *Heart*; 91:369–370.
- 79- Lechat P, Hulot JS, Escolano S et al. (2001):** Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. *Circulation*; 103: 1428 – 1433.
- 80- Lehto M, Snapinn S, Dickstein K et al. (2005):** Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. *Eur Heart J*; 26:350-356.
- 81- Levy S (2000)** "Classification system of atrial fibrillation". *Curr Opin Cardiol*; 15: 54–57.

- 82- Levy S, Maarek M, Coumel P et al. (1999):** Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. *Circulation*; 99:3028–3035.
- 83- Lip Gregory YH, Hart Robert G and Conway Dwayne SG (2002):** ABC of anti-thrombotic therapy. Anti-thrombotic therapy for atrial fibrillation. *BMJ*; 325: 1022–1025.
- 84- Lloyd-Jones DM, Wang TJ, Leip EP et al. (2004):** Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. *Circulation*; 110:1042–1046.
- 85- Loh E, Sutton MS, Wun CC et al. (1997):** Ventricular dysfunction and the risk of stroke after myocardial infarction. *N Engl J Med*; 336:1916.
- 86- Lokshyn S, Mewis C and Kuhlkamp V (2000):** Atrial fibrillation in coronary artery disease. *Am J Cardiol*; 72:133–136.
- 87- Lopes RD, Pieper KS, Horton JR et al. (2008):** Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. *Heart*; 94: 867–873.
- 88- Madrid AH, Bueno MG, Rebollo JM et al. (2002):** Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. *Circulation*; 106:331–336.
- 89- Maggioni AP, Latini R, Carson PE et al. (2005):** Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). *Am Heart J*; 149: 548–557.
- 90- Marin F, Roldan V, Climent VE et al. (2004):** Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation. *Heart*; 90:1162–1166.

- 91- Marshall HJ, Harris ZI, Griffith MJ et al. (1999):** Prospective randomized study of ablation and pacing versus medical therapy for paroxysmal atrial fibrillation: effects of pacing mode and mode-switch algorithm. *Circulation*; 99:1587–1592.
- 92- McCaig LF and Burt CW. (2002):** National Hospital Ambulatory Medical Care Survey: 2002 emergency department summary. Advance data from Vital and Health Statistics, Atlanta, GA, CDC.
- 93- McMurray J, Kober L, Robertson M et al. (2005):** Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. *J Am Coll Cardiol*; 45:525–530.
- 94- Mehta RH, Dabbous OH, Granger CB et al. (2003):** Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. *Am J Cardiol*; 92:1031–1036.
- 95- Michael E, Menachem C, Zeev R et al. (1998):** Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era. *Circulation*; 97:965–970.
- 96- Mitusch R, Garbe M, Schmucker G et al. (1995):** Relation of left atrial appendage function to the duration and reversibility of non-valvular atrial fibrillation. *Am J Cardiol*; 75:944–947.
- 97- Mitusch R, Lange V, Stierle U et al. (1995):** Trans-esophageal echocardiographic determinants of embolism in non-rheumatic atrial fibrillation. *Int J Card Imaging*; 11:27–34.
- 98- Montalescot G, Sideris G, Meuleman C et al. (2006):** A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: The ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation, and Ongoing Necrosis) trial. *J Am Coll Cardiol*; 48:931-938.
- 99- Moses JW, Leon MB, Popma JJ et al. (2003):** Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. *N Engl J Med*; 349:1315-1323.

- 100- Mugge A, Kuhn H, Nikutta P et al. (1994):** Assessment of left atrial appendage function by biplane trans-esophageal echocardiography in patients with non-rheumatic atrial fibrillation: identification of a subgroup of patients at increased embolic risk. *J Am Coll Cardiol*; 23:599–607.
- 101- Nattel S (2002):** New ideas about atrial fibrillation 50 years on. *Nature*; 415:219–226.
- 102- Neumann FJ, Kastrati A, Pogatsa-Murray G et al. (2003):** Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. *JAMA*; 290:1593–1599.
- 103- Okin PM, Roman MJ, Devereux RB, et al. (1995):** Electrocardiographic identification of left ventricular mass by simple voltage-duration products. *J Am Coll Cardiol*; 25:417–423.
- 104- Olgin JE, Sih HJ, Hanish S et al. (1998):** Heterogeneous atrial denervation creates substrate for sustained atrial fibrillation. *Circulation*; 98: 2608 –2614.
- 105- Olgin JE and Zipes DP (2005):** Specific arrhythmias: diagnosis and treatment. Braunwald's heart disease: a textbook of cardiovascular medicine, 7th ed. Philadelphia: *WB Saunders*; 803–836.
- 106- Opolski G, Torbicki A, Kosior DA et al. (2004):** for the Investigators of the Polish HOT CAFE Trial. *Chest*; 126: 476–486.
- 107- O'Rourke RA, Hochman JS, Cohen MC et al. (2001):** New approaches to diagnosis and management of unstable angina and non-ST-segment elevation myocardial infarction. *Arch Intern Med*; 161:674–682.
- 108- Padanilam BJ and Prystowsky EN (2005):** Atrial fibrillation should ablation be first-line therapy and for whom: antagonist position. *Circulation*; 112(8): 1223–1229.
- 109- Page RL (2004):** Clinical practice. Newly diagnosed atrial fibrillation. *N Engl J Med*; 351:2408–2416.

- 110- Page RL, Tilsch TW, Connolly SJ et al. (2003):** Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide. *Circulation*; 107:1141–1145.
- 111- Page RL, Wharton JM and Prystowsky EN (1996):** Effect of continuous vagal enhancement on concealed conduction and refractoriness within the Atrio-ventricular node. *Am J Cardiol*; 77:260–265.
- 112- Pedersen OD, Bagger H, Kober L et al. (1999):** The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. *Eur Heart J*; 20: 748– 754.
- 113- Pedersen OD, Bagger H, Kober L et al. (1999):** Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. *Circulation*; 100:376–380.
- 114- Pedersen OD, Abildstrøm SZ, Ottesen MM et al. (2006):** TRACE Study Investigators. Increased risk of sudden and non-sudden cardiovascular death in patients with atrial fibrillation/flutter following acute myocardial infarction. *Eur Heart J*; 27:290–295.
- 115- Pelargonio G and Prystowsky EN (2005):** Rate versus rhythm control in the management of patients with atrial fibrillation. *Nat Clin Pract*; 2:514-521.
- 116- Peters RJ, Mehta SR, Fox KA et al. (2003):** Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. *Circulation*; 108:1682-1687.
- 117- Pifarre R and Scanlon P (2001):** Evidence-based management of the acute coronary syndrome. Philadelphia: Hanley & Belfus, Inc.
- 118- Pizzetti F, Turazza FM, Franzosi MG et al. (2001):** Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. *Heart*; 86: 527–532.

- 119- Podrid PJ (2006):** Supra-ventricular arrhythmias after myocardial infarction. Up to date. 14.2 ed.
- 120- Pokharel S, van Geel PP, Sharma UC et al. (2004):** Increased myocardial collagen content in transgenic rats overexpressing cardiac angiotensin converting enzyme is related to enhanced breakdown of N-acetyl-Ser-Asp-Lys-Pro and increased phosphorylation of Smad2/3. *Circulation*; 110:3129–3135.
- 121- Polontchouk L, Haefliger JA, Ebel B et al. (2001):** Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria. *J Am Coll Cardiol*; 38:883–891.
- 122- Prystowsky EN (1997):** Atrioventricular node reentry: physiology and radiofrequency ablation. *Pacing Clin Electrophysiol*; 20:552–571.
- 123- Prystowsky EN (2000):** Management of atrial fibrillation: therapeutic options and clinical decisions. *Am J Cardiol*; 85:3-11.
- 124- Prystowsky EN (2006):** Assessment of rhythm and rate control in patients with atrial fibrillation. *J Cardiovasc Electrophysiol*; 17: 7–10.
- 125- Prystowsky EN and Katz AM (1998):** Atrial fibrillation. In: Textbook of Cardiovascular Medicine. Philadelphia: Lippincott-Raven, 1661.
- 126- Psaty BM, Manolio TA, Kuller LH et al. (1997):** Incidence of and risk factors for atrial fibrillation in older adults. *Circulation*; 96:2455–2461.
- 127- Rathore SS, Berger AK, Weinfurt KP et al. (2000):** Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. *Circulation*; 101:969 –974.
- 128- Ricard P, Levy S, Trigano J et al. (1997):** Prospective assessment of the minimum energy needed for external electrical cardioversion of atrial fibrillation. *Am J Cardiol*; 79:815–826.
- 129- Rich JD, Maraganore JM, Young E et al. (2007):** Heparin resistance in acute coronary syndromes. *J Thromb Thrombolysis*; 23:93-100.

- 130- Richards AM, Nicholls MG, Troughton RW, et al. (2002):** Antecedent hypertension and heart failure after myocardial infarction. *JACC*; 39: 1182–1188
- 131- Ruo B, Capra AM, Jensvold NG et al. (2004):** Racial variation in the prevalence of atrial fibrillation among patients with heart failure: the Epidemiology, Practice, Outcomes, and Costs of Heart Failure (EPOCH) study. *J Am Coll Cardiol*; 43: 429–435.
- 132- Sanders P, Morton JB, Davidson NC et al. (2003):** Electrical remodeling of the atria in congestive heart failure: electrophysiological and electro-anatomic mapping in humans. *Circulation*; 108:1461–1468.
- 133- Savonitto S, Ardissino D, Granger CB et al. (1999):** Prognostic value of the admission electrocardiogram in acute coronary syndromes. *JAMA*; 281:707-713.
- 134- Schmieder RE, Martus P and Klingbeil A (1996):** Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. *JAMA*; 275:1507–1513.
- 135- Schmitt J, Duray G, Gersh BJ et al. (2009):** Atrial fibrillation in acute myocardial infarction: A systematic review of the incidence, clinical features and prognostic implications. *Eur Heart J*, 30: 1038–1045.
- 136- Schwartzman D, Bazaz R and Nosbisch J (2004):** Common left pulmonary vein: a consistent source of arrhythmogenic atrial ectopy. *J Cardiovasc Electrophysiol*; 15:560–566.
- 137- Scott PA, Pancioli AM, Davis LA et al. (2002):** Prevalence of atrial fibrillation and antithrombotic prophylaxis in emergency department patients. *Stroke*; 33: 266- 294.
- 138- Serrano CV Jr, Ramires JA, Mansur AP et al. (1995):** Importance of the time of onset of supra-ventricular tachyarrhythmias on prognosis of patients with acute myocardial infarction. *Clin Cardiol*; 18:84–90.
- 139- Shah D, Haissaguerre M, Jais P et al. (2003):** Non-pulmonary vein foci: do they exist? *Pacing Clin Electrophysiol*; 26:1631–1635.

-
- 140- Shinagawa K, Shiroshita-Takeshita A, Schram G et al. (2003):** Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone. *Circulation*; 107:1440–1446.
- 141- Shiroshita-Takeshita A, Schram G, Lavoie J et al. (2004):** Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by Atrial-tachycardia remodeling in dogs. *Circulation*; 110:2313–2319.
- 142- Siu CW, Jim MH, Ho HH et al. (2007):** Transient Atrial Fibrillation Complicating Acute Inferior Myocardial Infarction. *Chest*; 132:44–49.
- 143- Stewart S, Hart CL, Hole DJ et al. (2002):** A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. *Am J Med*; 113:359–364.
- 144- Storey RF, May JA and Heptinstall S (2005):** Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y₁₂ and P2Y₁ antagonists but not aspirin. *Thromb Res*; 115:301-307.
- 145- Tai CT, Chen SA, Tzeng JW et al. (2001):** Prolonged fractionation of paced right atrial electrograms in patients with atrial flutter and fibrillation. *J Am Coll Cardiol*; 37:1651–1657.
- 146- Thambidorai SK, Parakh K, Martin DO et al. (2004):** Relation of C-reactive protein correlates with risk of thrombo-embolism in patients with atrial fibrillation. *Am J Cardiol*; 94:805–807.
- 147- The TIMI IIIB Investigators. (1994):** Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB Trial. *Circulation*; 89:1545-1556.
- 148- Tjandrawidjaja MC, Fu Y, Kim DR et al. (2005):** Compromised atrial coronary anatomy is associated with atrial arrhythmia and atrio-ventricular block complicating acute myocardial infarction. *J Electrocardiol*; 38:271-278.
-

- 149- Topol EJ, Easton D, Harrington RA et al. (2003):** Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. *Circulation*; 108:399-406.
- 150- Tsang TS, Gersh BJ, Appleton CP et al. (2002):** Left ventricular diastolic dysfunction as a predictor of the first diagnosed non-valvular atrial fibrillation in 840 elderly men and women. *J Am Coll Cardiol*; 40:1636–1644.
- 151- Van Den Berg MP, Crijns HJ, Haaksma J et al. (1994):** Analysis of vagal effects on ventricular rhythm in patients with atrial fibrillation. *Clin Sci (Colch)*; 86:531–535.
- 152- Van Den Berg MP, Tuinenburg AE, Van Veldhuisen DJ et al. (1998):** Cardioversion of atrial fibrillation in the setting of mild to moderate heart failure. *Int J Cardiol*; 63:63–70.
- 153- Wang TJ, Larson MG, Levy D et al. (2003):** Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. *Circulation*; 107:2920–2925.
- 154- Warkentin TE and Kelton JG (2001):** Temporal aspects of heparin-induced thrombocytopenia. *N Engl J Med*; 344:1286-1292.
- 155- Waters D (2001):** Diagnosis and management of patients with unstable angina. Fuster V, Alexander RW, O'Rourke RA, et al, editors. *Hurst's the Heart* (10th ed). *New York: McGraw-Hill*: 2129-2142.
- 156- Weyman AE. (1994):** Physical principles of ultrasound. In: Weyman AE, ed. *Principles and Practice of Echocardiography*, 2nd ed. Philadelphia: Lea & Febiger: 3–28.
- 157- Willems JL, Robles Da Medina EO, Bernard R, et al. (1985):** Criteria for intraventricular conduction disturbances and pre-excitation. *J Am Coll Cardiol*; 5: 1261-1275.

- 158- Wiviott SD, Antman EM, Winters KJ et al. (2005):** Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y₁₂ antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. *Circulation*; 111:3366-3373.
- 159- Wong CK, White HD, Wilcox RG et al. (2000):** New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. *Am Heart J*; 140:878–885.
- 160- Wong CK, White HD, Wilcox RG et al. (2002):** Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries. *Heart*; 88:357-362.
- 161- Wu AH, Apple FS, Gibler WB et al. (1999):** National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. *Clin Chem*; 45:1104–1121.
- 162- Yusuf S, Mehta SR, Chrolavicius S et al. (2006):** Comparison of fondaparinux and enoxaparin in acute coronary syndromes. *N Engl J Med*; 354:1464-1476.
- 163- Yusuf S, Sleight P, Pogue J et al. (2000):** Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med*; 342:145–153.
- 164- Zile MR, Baicu CF, Gaasch WH (2004):** Diastolic heart failure: abnormalities in active relaxation and passive stiffness of the left ventricle. *N Engl J Med*; 350:1953.
- 165- Zimetbaum PJ, Josephson ME, McDonald MJ et al. (2000):** Incidence and predictors of myocardial infarction among patients with atrial fibrillation. *J Am Coll Cardiol*; 36: 1223-1227.